Rethinking Antibiotic Strategy in Infected Necrotizing Pancreatitis | Journal of Antimicrobial Chemotherapy

Introduction

Infected necrotizing pancreatitis remains one of the most severe complications of acute pancreatitis and is associated with substantial morbidity, organ failure and mortality. Management relies on timely antimicrobial therapy combined with delayed, minimally invasive source control strategies. However, optimal antibiotic selection remains controversial because treatment is frequently empirical and microbiological confirmation is often unavailable early in the disease course.

Problem Statement

Traditional management has favored carbapenems because of presumed superior pancreatic penetration, yet increasing antimicrobial resistance and prolonged antibiotic exposure are reshaping the microbiology of infected pancreatic necrosis. At the same time, uncertainty persists regarding the true role of anaerobes, enterococci and fungal pathogens, while inappropriate empirical therapy remains common and may contribute to worse outcomes and multidrug resistance.

Summary

This comprehensive review highlights the evolving microbiological and pharmacokinetic landscape of infected necrotizing pancreatitis and challenges several long-standing assumptions regarding antimicrobial therapy. The microbiology is predominantly enteric, with Gram-negative organisms such as Escherichia coli and Klebsiella species remaining the dominant pathogens, although prolonged hospitalization and cumulative antibiotic exposure increasingly select for multidrug-resistant organisms, enterococci and fungal infections. Importantly, the review emphasizes that prophylactic antibiotics do not prevent infected necrosis or improve mortality and therefore should not be routinely used. The authors also question the traditional preference for carbapenems, noting that pharmacokinetic studies demonstrate that piperacillin-tazobactam and advanced-generation cephalosporins can achieve adequate penetration into necrotic pancreatic tissue, particularly when administered using extended infusion strategies. Molecular diagnostic studies further suggest that anaerobic organisms are substantially underrecognized by conventional culture techniques, supporting the rationale for empirical anaerobic coverage despite low reported culture yields. The review advocates for more individualized antimicrobial selection based on local resistance patterns, previous antibiotic exposure and evolving disease phase, while reserving carbapenems for multidrug-resistant infections or clinical failure. Overall, this work supports a more stewardship-focused, pharmacokinetically informed approach to antimicrobial therapy in infected necrotizing pancreatitis.